Table 1 Baseline characteristics of patients included in the study
Parameter | Non-responders | Responders | P value | DAS28 > 3.2 (week 24) | DAS28 ≤ 3.2 (week 24) | P value |
|---|---|---|---|---|---|---|
(n = 11) | (n = 33) | (n = 29) | (n = 15) | |||
Age in years (mean ± SD) | 58.9 ± 10.8 | 62.5 ± 13.3 | 0.423 | 61.8 ± 13.8 | 61.3 ± 10.7 | 0.898 |
Female gender, % | 72 | 81 | 0.640 | 76 | 87 | 0.411 |
Disease duration in years (mean ± SD) | 15.1 ± 12.7 | 12.9 ± 8.8 | 0.536 | 12.7 ± 10.5 | 15.4 ± 8.1 | 0.428 |
DAS28-ESR (mean ± SD) | 5.0 ± 1.1 | 6.0 ± 1.1 | 0.008 | 5.8 ± 1.1 | 5.7 ± 1.3 | 0.753 |
RF-positive, % | 100 | 87 | 0.236 | 86 | 100 | 0.138 |
ACPA-positive, % | 78 | 76 | 0.909 | 72 | 85 | 0.399 |
Corticosteroids, % | 36 | 30 | 0.061 | 34 | 26 | 0.608 |
Previous TNF inhibitors (mean ± SD) | 1.7 ± 1.2 | 1.2 ± 0.9 | 0.194 | 1.5 ± 1.1 | 1.2 ± 0.7 | 0.346 |